The main challenges in the treatment of T-cell lymphoblastic lymphoma (T-LBL) in children and adolescents are twofold: to increase survival rates in concert with reduction of acute and long-term toxicities including the rate of secondary malignancies. The need for molecular and prognostic markers in T-LBL is crucial to allow for systematic treatment optimization and may serve as targets for new treatment approaches.
Keywords: Paediatric T-lymphoblastic lymphoma; genetic classifier; molecular markers; risk group stratification; treatment.
© 2016 John Wiley & Sons Ltd.